Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC |
Milligan SandraHead of Research & Development
|
Exercise / conversionCommon Stock | 10,171 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-029457 · tm228175-5_4seq1.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC |
Ali KevinDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 14,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029456 · tm228175-4_4seq1.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,529 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F3 · shares: The amount of the Restricted Stock Units has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC |
Ali KevinDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 6,469 | $37.57 | $243,040.33 |
DisclosureSEC source: 0001104659-22-029456 · tm228175-4_4seq1.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,462 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC |
Ali KevinDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 14,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-029456 · tm228175-4_4seq1.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:45 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionRestricted Stock Units · Derivative | 5,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029453 · tm228175-3_4seq1.xml · derivative · entry 3 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,813 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F3 · shares: The amount of the Restricted Stock Units has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:45 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Tax withholdingCommon Stock | 1,717 | $37.57 | $64,507.69 |
DisclosureSEC source: 0001104659-22-029453 · tm228175-3_4seq1.xml · nonDerivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,669 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:45 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionCommon Stock | 5,813 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-029453 · tm228175-3_4seq1.xml · nonDerivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:44 UTC |
Ritter Geralyn SHd of Ext. Affairs and ESG
|
Exercise / conversionRestricted Stock Units · Derivative | 3,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029452 · tm228175-2_4seq1.xml · derivative · entry 3 Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,777 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F3 · shares: The amount of the Restricted Stock Units has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:44 UTC |
Ritter Geralyn SHd of Ext. Affairs and ESG
|
Tax withholdingCommon Stock | 1,366 | $37.57 | $51,320.62 |
DisclosureSEC source: 0001104659-22-029452 · tm228175-2_4seq1.xml · nonDerivative · entry 2 Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,663 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:44 UTC |
Ritter Geralyn SHd of Ext. Affairs and ESG
|
Exercise / conversionCommon Stock | 3,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-029452 · tm228175-2_4seq1.xml · nonDerivative · entry 1 Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:43 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029451 · tm228175-1_4seq1.xml · derivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,795 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F3 · shares: The amount of the Restricted Stock Units has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:43 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 1,727 | $37.57 | $64,883.39 |
DisclosureSEC source: 0001104659-22-029451 · tm228175-1_4seq1.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,369 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:43 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 4,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-029451 · tm228175-1_4seq1.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:10 UTC |
DiMarco KathrynCorporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 1,869 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-005697 · doc4.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,740 Underlying: Common Stock · 1,869 shares Expires 2024-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On June 2, 2021 in connection with the separation of Organon from Merck & Co., Inc., the restricted stock unit award was converted into a restricted stock unit award with 5,609 shares of Organon common stock underlying such award. These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments. The first installment vested and has been distributed on February 9, 2022. The remaining installments will vest and be distributed on each of February 9, 2023 and February 9, 2024. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:10 UTC |
DiMarco KathrynCorporate Controller
|
Tax withholdingCommon Stock | 745 | $33.75 | $25,143.75 |
DisclosureSEC source: 0000899243-22-005697 · doc4.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,927 Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:10 UTC |
DiMarco KathrynCorporate Controller
|
Exercise / conversionCommon Stock | 1,869 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-005697 · doc4.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. Read SEC document |
| August 19, 2021 Filed Aug 19, 2021 21:11 UTC |
Francisco Ma. FatimaDirector
|
PurchaseCommon Stock | 3,000 | $33.79 | $101,370.00 |
DisclosureSEC source: 0000899243-21-033675 · doc4.xml · nonDerivative · entry 1 Francisco Ma. Fatima · CIK 0001747222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 17:09 UTC |
Fiedler SusanneChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033672 · doc4.xml · derivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 17:04 UTC |
DiMarco KathrynCorporate Controller
|
GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033663 · doc4.xml · derivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:03 UTC |
Telman Deborah HGen Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033661 · doc4.xml · derivative · entry 1 Telman Deborah H · CIK 0001860008 · Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:08 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 44,642 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033670 · doc4.xml · derivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,642 Underlying: Common Stock · 44,642 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 17:08 UTC |
Stahler Rachel AChief Information Officer
|
GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033669 · doc4.xml · derivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:14 UTC |
Milligan SandraHead of Research & Development
|
GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033677 · doc4.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:11 UTC |
Nisita VittorioHead of Global Business Svcs
|
GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033674 · doc4.xml · derivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:05 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033665 · doc4.xml · derivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:00 UTC |
Falcione AaronChief Human Resources Officer
|
GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033656 · doc4.xml · derivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:04 UTC |
Ritter Geralyn SHd of Ext. Affairs and ESG
|
GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033664 · doc4.xml · derivative · entry 1 Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 20:59 UTC |
Ali KevinDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 133,928 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033654 · doc4.xml · derivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,928 Underlying: Common Stock · 133,928 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:47 UTC |
Telman Deborah HEVP GC & Corporate Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 6,445 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032181 · doc4.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,892 Underlying: Common Stock · 6,445 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:47 UTC |
Telman Deborah HEVP GC & Corporate Secretary
|
Tax withholdingCommon Stock | 1,889 | $28.63 | $54,082.07 |
DisclosureSEC source: 0000899243-21-032181 · doc4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,556 Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:47 UTC |
Telman Deborah HEVP GC & Corporate Secretary
|
Exercise / conversionCommon Stock | 6,445 | $28.63 | $184,520.35 |
DisclosureSEC source: 0000899243-21-032181 · doc4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:44 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 22,343 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032176 · doc4.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,690 Underlying: Common Stock · 22,343 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:44 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 7,653 | $28.63 | $219,105.39 |
DisclosureSEC source: 0000899243-21-032176 · doc4.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,690 Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:44 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionCommon Stock | 22,343 | $28.63 | $639,680.09 |
DisclosureSEC source: 0000899243-21-032176 · doc4.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:46 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 12,890 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032180 · doc4.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,785 Underlying: Common Stock · 12,890 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:46 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 4,416 | $28.63 | $126,430.08 |
DisclosureSEC source: 0000899243-21-032180 · doc4.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,474 Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:46 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionCommon Stock | 12,890 | $28.63 | $369,040.70 |
DisclosureSEC source: 0000899243-21-032180 · doc4.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:41 UTC |
Ozuah PhilipDirector
|
GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022685 · doc4.xml · derivative · entry 1 Ozuah Phillip · CIK 0001859685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F2 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:33 UTC |
LAZARUS ROCHELLE BDirector
|
GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022672 · doc4.xml · derivative · entry 3 LAZARUS ROCHELLE B · CIK 0001082206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F2 · derivative.exercise_price: 1-for-1 F3 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F3 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:44 UTC |
COX CARRIE SMITHDirector
|
GrantPhantom Stock · Derivative | 18,079 | $36.05 | $651,747.95 |
DisclosureSEC source: 0000899243-21-022688 · doc4.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,079 Underlying: Common Stock · 18,079 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Consists of (i) a one-time grant of 14,856 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F2 · derivative.expiration_date: Consists of (i) a one-time grant of 14,856 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:39 UTC |
Ezekowitz AlanDirector
|
GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022682 · doc4.xml · derivative · entry 1 Ezekowitz Alan · CIK 0001780209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F2 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:32 UTC |
Gayle Helene DDirector
|
GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022671 · doc4.xml · derivative · entry 1 Gayle Helene D · CIK 0001487047 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F2 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:36 UTC |
ESSNER ROBERTDirector
|
GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022677 · doc4.xml · derivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F2 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:31 UTC |
Sharp ShaliniDirector
|
GrantPhantom Stock · Derivative | 9,061 | $36.05 | $326,649.05 |
DisclosureSEC source: 0000899243-21-022669 · doc4.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,061 Underlying: Common Stock · 9,061 shares Expires not disclosed F2 · derivative.exercise_price: 1-for-1 F3 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,512 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F3 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,512 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:41 UTC |
Patton Cynthia MDirector
|
GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022684 · doc4.xml · derivative · entry 1 Patton Cynthia M · CIK 0001560565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F2 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:36 UTC |
Whiteford Grace PumaDirector
|
GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022676 · doc4.xml · derivative · entry 2 Whiteford Grace Puma · CIK 0001706213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F2 · derivative.exercise_price: 1-for-1 F3 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F3 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:29 UTC |
Francisco Ma. FatimaDirector
|
GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022666 · doc4.xml · derivative · entry 1 Francisco Ma. Fatima · CIK 0001747222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F2 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:41 UTC |
McGarry Martha EDirector
|
GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022686 · doc4.xml · derivative · entry 1 McGarry Martha E · CIK 0001859699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F2 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:37 UTC |
Leone Deborah RDirector
|
GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022678 · doc4.xml · derivative · entry 2 Leone Deborah R · CIK 0001859703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F2 · derivative.exercise_price: 1-for-1 F3 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F3 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC |
Fiedler SusanneChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 115,980 | $0.00 Strike: $36.11 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 13 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,980 Underlying: Common Stock · 115,980 shares Expires 2031-05-03 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F12 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.